ALIAKBAR R DADLA
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology VANCOUVER, WA NPI 1134474976
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology WA PFIZER INC. All categories
General Payments — all program years on this page
$4,438.64
- Category: General Payments
- Program years: PY2018–2024
- Record count: 252
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,111.78 across 60 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $971.29 | 48 |
| Education | $140.49 | 12 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $213.92 | 17 |
| Merck Sharp & Dohme Corporation | $188.21 | 9 |
| Acerta Pharma LLC | $138.98 | 7 |
| Daiichi Sankyo Inc. | $89.90 | 4 |
| ABBVIE INC. | $56.55 | 3 |
| E.R. Squibb & Sons, L.L.C. | $42.57 | 2 |
| Janssen Biotech, Inc. | $42.09 | 2 |
| Stemline Therapeutics Inc. | $34.11 | 2 |
| Coherus Biosciences Inc. | $33.31 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.26 | 1 |
| BeiGene USA, Inc. | $31.07 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.49 | 1 |
| Regeneron Healthcare Solutions, Inc. | $26.21 | 1 |
| GENZYME CORPORATION | $24.94 | 1 |
| Mirati Therapeutics, Inc. | $22.04 | 1 |
| Genmab U.S., Inc. | $21.57 | 1 |
| Deciphera Pharmaceuticals Inc. | $20.85 | 1 |
| Celgene Corporation | $19.80 | 1 |
| GlaxoSmithKline, LLC. | $16.42 | 1 |
| Incyte Corporation | $16.27 | 1 |
| EISAI INC. | $13.22 | 1 |
By program year
Records — PY2024 (60)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.